Related Experiment Videos
[Cryptococcosis of the central nervous system]
Boletin Medico Del Hospital Infantil De Mexico
|January 1, 1977
Summary
This study explored combined 5-flurocytosine and amphotericin B for Cryptococcus meningitidis treatment. The combination therapy proved safe and effective, reducing toxicity and hospitalization time without relapse.
Area of Science:
- Infectious Diseases
- Mycology
- Pharmacology
Background:
- Cryptococcus meningitidis causes meningitis, a serious infection.
- Standard treatments for cryptococcal meningitis can have significant toxicity and prolonged hospitalization.
- Exploring alternative therapeutic regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of combined 5-flurocytosine and amphotericin B therapy.
- To assess if combination therapy offers superior clinical response compared to monotherapy.
- To reduce drug toxicity and shorten treatment duration and hospitalization periods.
Main Methods:
- Case series detailing diagnosis, treatment, and clinical course of three patients.
- One patient received 5-flurocytosine monotherapy.
- Two patients received combination therapy with 5-flurocytosine and amphotericin B for four weeks.
Main Results:
- No relapses were observed in any of the treated patients.
- Combination therapy demonstrated reduced toxicity.
- Shorter hospitalization periods were noted in patients receiving combination therapy.
Conclusions:
- Combined 5-flurocytosine and amphotericin B therapy is a safe and effective alternative for treating Cryptococcus meningitidis infections.
- This regimen potentially reduces treatment-related toxicity and shortens hospital stays.
- Further studies could validate these findings in larger patient cohorts.